



Index

Note: Page numbers of article titles are in **boldface** type.

A

- Abdominal muscle strength, evaluation of, for pain management, 342
- Acetylcholine modulators, intrathecal delivery of, 361
- Adenoassociated virus, for gene transfer, for pain management, 423–424
- Adenovirus, for gene transfer, for pain management, 422–423, 428, 430
- α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors, in pain transmission, 451–452
- Analgesia
 - intrathecal delivery of. *See* Intrathecal pain management.
 - pre-emptive, 452
- Anderson-Fabry disease, pain in, gene therapy for, 431
- Anesthesia dolorosa, deep brain stimulation for, 333
- Angiostatin gene transfer, for pain management, 430–431
- Antinociception, physiology of, 452–454
- Aspartylacylase deficiency, gene therapy for, 431

B

- Baclofen, intrathecal delivery of, 360–361
- Bone morphogenic protein gene transfer, for pain management, 430
- Brain
 - deep stimulation of. *See* Deep brain stimulation.
 - precentral stimulation of, 334, **437–443**
 - sensitization in, physiology of, 450–452
- Brain-derived neurotrophic factor, in antinociception, 454

C

- Calcitonin gene-related peptide, in pain transmission, 446, 452
- Calcium, in pain transmission, 451–452
- Calcium channel blockers, intrathecal delivery of, 361
- Canavan disease, gene therapy for, 431
- Cancer pain
 - definition of, 330
 - intrathecal management of, 355, 359, 361, 383–385
- Catheters, for intrathecal pain management, 356–358, 382–383
- Cationic polymers, for gene transfer, 421
- Cauda equina syndrome, in intrathecal medication delivery, 358
- Central sensitization, physiology of, 450–452
- Cerebrospinal fluid leakage, in intrathecal medication delivery, 358
- Chromaffin cells, intrathecal delivery of, 361
- Cingulate cortex, in nociception, 448
- Clonidine, intrathecal delivery of, 360, 384
- Coccydynia, spinal cord stimulation for, 378
- Compensation systems, pain management and, 341, 349–350
- Complex regional pain syndrome, spinal cord stimulation for, 378
- Conus medullaris compression, in intrathecal medication delivery, 358
- Cordotomy, for pain, 328
- Cre-lox system, for gene transfer, for pain management, 422
- Cystitis, interstitial, peripheral nerve stimulation for, 377

Cytomegalovirus, for gene transfer, for pain management, 422

D

Deep brain stimulation, **389–399**

complications of, 395–396
for neuropathic pain, 390–391
for nociceptive pain, 391
history of, 332–334, 389–390
mechanism of action for, 390–391
off-label use of, 396
patient selection for, 391–392
physiology of, 454–455
preoperative evaluation for, 391–392
rationale for, 390–391
results of, 394–396
target site selection for, 392
technique for, 392–394
tolerance to, 395

Depression

evaluation of, before pain management, 411–412, 414–415
treatment of, before pain management, 348

Diabetic neuropathy, pain in

gene therapy for, 430
spinal cord stimulation for, 378

DNA, in gene therapy, for pain, 420–421, 427–430

Dopamine deficiency, gene therapy for, 426

Dynorphin, in antinociception, 453

E

Edema, in intrathecal morphine delivery, 385–386

Electrical stimulation

deep brain, 332–334, **389–399**
implantable stimulators for, 331–334, 372–375, 403–406
motor cortex, 334
peripheral nerve, 331, **401–408**
precentral, 334, **437–443**
spinal cord, 331–332, **365–380**

Electropermeabilization, in gene therapy, for pain, 420

Endometriosis, pain in, gene therapy for, 430–431

Enkephalins, in antinociception, 453

Equine infectious anemia virus, for gene transfer, for pain management, 425

F

Federal Employees' Compensation Act, 349

Federal Employers' Liability Act, 349

Feline immunodeficiency virus, for gene transfer, for pain management, 425

Foreign body reactions, in deep brain stimulation, 395

G

α -Galactosidase A deficiency, pain in, gene therapy for, 431

Gamma-aminobutyric acid

deficiency of, gene therapy for, 426
receptors for, in antinociception, 453–454

Gasserian ganglion, in nociception, 446–447

Gate theory of pain, 328–331, 451

Gene-gun method, for gene transfer, 428

Gene therapy, for pain, **419–435**

advantages of, 419, 422
cell lines for, 429–430
complications of, 430
ex vivo, 429–430
neuromodulation, 425–429
nonviral, 420–421
root causes, 429–430
viral vectors in, 421–425

Glial-derived neurotrophic factor, in nociception, 446

Glial fibrillary acidic protein, for gene transfer, for pain management, 422

Glutamate, in pain transmission, 451–452

Glutamate decarboxylase deficiency, gene therapy for, 426

Glycine, intrathecal delivery of, 360

Granuloma, at catheter tip, in intrathecal drug delivery, 386

H

Headache

from deep brain stimulation, 396
peripheral nerve stimulation for, 404–405

Hemorrhage, intracranial, in deep brain stimulation, 395

Herniorrhaphy, postoperative pain in, peripheral nerve stimulation for, 406

Herpes simplex virus 1, for gene transfer, for pain management, 424–425, 428–429

Human immunodeficiency virus, for gene transfer, for pain management, 425

Hyperalgesia

central mechanisms of, 450–451
in gene therapy for pain, 431

Hypoxanthine-guanine phosphoribosyltransferase gene transfer, 422–423

I

Implantable devices, for pain management
electrical stimulation, 331–334, 372–375

peripheral nerve, 403–406
spinal cord, 372–375

intrathecal drug delivery, 331–334, 372–375

Infections

in deep brain stimulation, 395
in intrathecal medication delivery, 357
in spinal cord stimulation, 375–376

Inflammation, at catheter tip, in intrathecal drug delivery, 386

Inguinal pain, peripheral nerve stimulation for, 406

Inositol triphosphate, in pain transmission, 452

Insula, in nociception, 448

Interleukin-12 gene transfer, for pain, 427–428

Intrathecal pain management, 353–363

complications of, 358–359
contraindications to, 355
delivery of, **381–387**
clinical studies of, 383–385
inflammatory mass interference with, 386
pharmacodynamics of, 381–383
side effects of, 385–386
sites for, 354

devices for

evaluation of, 358
failure of, 358
implantation of, 357–358
management of, 359
replacement of, 359
selection of, 355–357

dose changes in, 359

drugs used in, 360–361

future of, 360–362

history of, 353–354

intraventricular route of, 354, 356

outcomes of, 359–360

patient selection for, 354–355

psychologic variables in, 410–412

trial of, 355

versus epidural delivery, 354

versus medical treatment, 383

K

Kainate receptors, in pain transmission, 451

Ketamine, intrathecal delivery of, 360

L

Laminotomy, for spinal cord stimulation implant, 375

Lentiviruses, for gene transfer, for pain management, 425

Liposome-mediated gene transfer, for pain, 421

Long Shore and Harbor Workers' Act, 349

M

Macrostimulation, in deep brain stimulation, 393

Magnetic resonance imaging

for deep brain stimulation, 392–393
for precentral stimulation, 438

Manganese superoxide dismutase gene transfer, for pain management, 430

Medical history, in pain management, review of, 340–342

Melzack-Wall gate theory of pain, 328–331, 451

Meningitis, in intrathecal medication delivery, 357–358

N-Methyl-D-aspartate (NMDA) receptors, in pain transmission, 451–453
antagonists of, 360

MK-801, intrathecal delivery of, 360

Morphine, intrathecal delivery of, 354, 358, 360
clinical studies of, 383–385
pharmacodynamics of, 381–383
side effects of, 385–386

Morphine-naloxone test, for deep brain stimulation preoperative evaluation, 391–392

Motivation, evaluation of, before pain management, 415

Motor cortex, stimulation of, 334, **437–443**

complications of, 441
indications for, 438
literature review on, 439–441

Motor (continued)

- mechanism of, 437–438
- technique for, 438–439

Myoclonus, in intrathecal morphine delivery, 385–386

N

Nerve(s), injury of, peripheral sensitization in, 449

Nerve fibers, sensory, physiology of, 445

Neuralgia, occipital, peripheral nerve stimulation for, 377–378

Neuroaugmentation. *See also specific techniques.*

definition of, 327

evaluation for, **339–352**

history of, **327–337**

deep brain stimulation, 332–334

early theories on, 327–328

gate theory, 328–331

motor cortex stimulation, 334

peripheral nerve stimulation, 331

spinal cord stimulation, 331–332

psychologic evaluation for, **409–417**

Neuroma, peripheral sensitization in, 449–450

Neuron specific enolase, for gene transfer, for pain management, 422

Neuropathic pain

deep brain stimulation for, 390–392, 394

spinal cord stimulation for, 378

Neuropeptide FF, in antinociception, 453

Neuropeptide Y, in antinociception, 453–454

Neurotrophic growth factors, in peripheral sensitization, 449–450

Nitric oxide, in peripheral sensitization, 450

NMDA (*N*-methyl-D-aspartate) receptors, in pain

transmission, 451–453

antagonists of, intrathecal delivery of, 360

Nociception

anatomy of, 445–448

receptors in, 448–449

Nociceptive pain, deep brain stimulation for, 391–392, 395

Norepinephrine, in nociception, 455

Nucleus raphe magnus, in nociception, 454–455

Nucleus ventralis posteromedialis, electrical stimulation of, 389, 391–393

O

Obesity, pain management and, 342

Occipital headache, peripheral nerve stimulation for, 377–378, 404–405

Octreotide, intrathecal delivery of, 361

Opioids. *See also* Morphine.

endogenous, in antinociception, 453

intrathecal delivery of, 354, 358

P

Pain, chronic, anatomy and physiology of, **445–462**

antinociception, 452–454

central sensitization, 450–452

descending systems, 454–455

nociception, 445–448

peripheral sensitization, 449–450

supraspinal plasticity, 455

supraspinal systems, 454–454

Pain evaluation, **339–352**

compensation systems and, 341, 349–350

for patient selection, 339–340

medical history review in, 340–342

physical findings in, 342–343

prior treatment evaluation, 345–347

psychologic report review in, 343–345

psychosocial issues in, 347–348

secondary gain and, 349

Pain management

anatomic and physiologic considerations in, **445–462**

compliance with, 343, 345

decision not to treat, 340

deep brain stimulation for, **389–399**

evaluation for, **339–352**

failure of, 339–340, 345

in spinal cord stimulation, 377, 410

gene therapy for, **419–435**

intrathecal medications for. *See* Intrathecal pain management.

neuroaugmentation for

evaluation for, **339–352**

history of, **327–337**

psychologic evaluation for, **409–417**

pain classification for, 329–330

peripheral nerve stimulation for. *See*

Peripheral nerve stimulation.

precentral stimulation for, 334, **437–443**

regression of benefit in, 339–340, 345

- spinal cord stimulation in. *See* Spinal cord stimulation.
- terminology of, 329–330
- Paleospinothalamic tract, in nociception, 447
- Paraplegia, in intrathecal drug delivery, 386
- Paresthesia, in spinal cord stimulation, 372, 377
- Parkinson's disease, gene therapy for, 426
- Pelvic pain, spinal cord stimulation for, 378
- Percutaneous implantation, for peripheral nerve stimulation, 403
- Periaqueductal gray matter. *See* Deep brain stimulation.
- Peripheral nerve stimulation, **401–408**
- complications of, 406
 - for occipital headache, 404–405
 - for postoperative inguinal pain, 406
 - for supraorbital pain, 405
 - history of, 331, 401
 - indications for, 401
 - mechanism of action of, 406–407
 - open nerve dissection technique for, 402–403
 - outcomes of, 407
 - patient selection for, 401–402
 - percutaneous implant technique for, 403
 - spinal cord stimulation equipment for, 377–378
 - subcutaneous, 403–406
 - techniques for, 402
- Peripheral sensitization, physiology of, 449–450
- Periventricular gray matter, electrical stimulation of. *See* Deep brain stimulation.
- Phantom limb pain, physiology of, 452
- Phospholipase C, in pain transmission, 452
- Physical therapy, for pain, 340
- Plasticity, supraspinal, in nociception, 455
- Polyethyleneimine, for gene transfer, 421
- Precentral stimulation, 334, **437–443**
- complications of, 441
 - indications for, 438
 - literature review on, 439–441
 - mechanism of, 437–438
 - technique for, 438–439
 - trial stimulation in, 439
- Preproenkephalin gene transfer, for pain management, 428–429
- Preprogalanin gene transfer, for pain management, 429
- Primary afferent depolarization, in antinociception, 453
- Proopiomelanocortin gene transfer, for pain, 427–428, 430
- Protein kinase C, in pain transmission, 452
- Psychiatric disorders, evaluation of, before pain management, 411–412, 414–415
- Psychologic evaluation, for neuroaugmentation, **409–417**
- contraindications identified in, 413–414
 - drug administration, 410–412
 - factors in, 414–416
 - instruments for, 415–416
 - need for, 409–410
 - personnel for, 412
 - procedure for, 412–413
 - spinal cord stimulation, 410–412
- Psychological issues, in pain management
- deep brain stimulation with, 391
 - depression, 348, 411–412, 414–415
 - intrathecal, 354
 - personal relationships, 348
 - preoperative psychologic evaluation, **409–417**
 - psychologist report review, 343–345
 - return to work, 347–348
 - substance abuse, 348
- Pumps, for intrathecal pain management, 356–359, 383–384
-
- R**
-
- Rabies-G pseudotyped lentivirus, for gene transfer, for pain management, 425
- Respiratory depression, in intrathecal pain management, 358
- Retroviruses, for gene transfer, for pain management, 425
- Rous sarcoma virus, for gene transfer, for pain management, 422
-
- S**
-
- Sacral pain, spinal cord stimulation for, 378
- Secondary gain, in pain
- chronic, 349
 - evaluation of, before management, 415
- Seizures, in precentral stimulation, 438, 441

Sensitization
 central, 450–452
 peripheral, 449–450

Seroma, in intrathecal medication delivery, 358

Smoking, pain management and, 343

Social Security programs, for chronic pain, 349–350

Somatosensory cortex, in nociception, 448

Somatosensory evoked potentials, in precentral stimulation, 439

Somatostatin, intrathecal delivery of, 361

Spinal cord
 compression of, in intrathecal medication delivery, 358
 dorsal horn of, reorganization of, in sensitization, 451
 dorsal root ganglia of, in nociception, 445–446
 laminar organization of, nociception and, 446–447

Spinal cord stimulation, **365–380**
 advantages of, 366
 applications of, 366–367, 377–378
 complications of, 374–377
 equipment for, 371–372
 in neuropathic pain, 378
 in peripheral nerve stimulation, 377–378
 failure of, 377, 410
 history of, 331–332, 365
 lead implants in, 372–374
 outcomes of, 367, 369–370, 409–412
 patient selection for, 367–370
 psychologic variables in, 409–412
 screening trial in, 371
 technique for, 370–375
 terminology of, 366

Spinal nucleus, in nociception, 447

Spinothalamic tract
 interruption of, for pain, 328
 lateral, in nociception, 446–447

Stereotactic surgery, for pain, 328, 438–439

Stimulation, electrical. *See* Electrical stimulation.

Subcutaneous implantation, for peripheral nerve stimulation, 403–406

Subnucleus caudalis, in nociception, 447

Substance abuse
 evaluation of, before pain management, 415
 treatment of, before pain management, 348

Substance P, in nociception, 446, 452, 454

Substantia gelatinosa, in nociception, 446

Superoxide dismutase gene transfer, for pain management, 430

Supraorbital pain, peripheral nerve stimulation for, 405

Sympathetic nervous system, peripheral sensitization in, 450

T

Tetracycline, for gene transfer, for pain management, 422

Thalamus
 electrical stimulation of. *See* Deep brain stimulation.
 nuclei of, in nociception, 447–448
 ventrobasal, electrical stimulation of, 332–333

Thermal injury, central sensitization in, 450–451

Transposons, for gene transfer, 421

Trigeminal mesencephalic nucleus, in nociception, 447

Trigeminal nerve, in nociception, 446–447

Trigeminothalamic tract, in nociception, 447

V

Ventroposterior nucleus, in nociception, 447

Vesiculostomatitis virus, for gene transfer, for pain management, 425

Viral vectors, for gene transfer, for pain management, 421–425

W

Wide dynamic range cells, in nociception, 446–447

Withdrawal reactions, in intrathecal pain management, 359

Work, return to, after pain management, psychosocial issues in, 347–348

Workers' compensation systems, pain management and, 341, 349–350